Neonc Technologies Holdings Inc (NTHI)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$3.27+10.85%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Neonc Technologies Holdings Inc’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	0
EPS	—	-0.292
Annual ending 2026-12-31
Revenue	—	39,990
EPS	—	-1.386
Annual ending 2027-12-31
Revenue	—	39,990
EPS	—	-1.107

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Reduce cash operating expenses to $10.1M annually	NeOnc aims to reduce cash operating expenses to about $10.1 million annually.	Under Pressure	cash operating expenses exceed $10.1 million in FY26	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
EPS loss narrows toward consensus estimates	Analysts have slightly improved EPS estimates from -$1.00 to -$0.85 for FY26.	Broken	EPS falls below -$0.85 for FY26	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Successful authorization and utilization of Series A Preferred Stock	The company has secured capital through Series A Preferred Stock to fund its cancer therapy pipeline.	Under Pressure	failure to deploy capital from Series A Preferred Stock by mid-2026	Series A Preferred Stock redeemed (0 shares outstanding) vs target: fully authorized and deployed by mid-2026 Sept 2026 8-K confirms redemption of all outstanding Series A Preferred Stock using proceeds from a $15M registered direct offering. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS: comparable history unavailable.

FY2027 revenue$0.00B

Unavailable → $0.00B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	Unavailable	Unavailable	2 / 4
2026-07-25	Unavailable	Unavailable	2 / 4
2026-07-26	Unavailable	Unavailable	2 / 4
2026-07-27	Unavailable	Unavailable	2 / 4
2026-07-28	Unavailable	Unavailable	2 / 4
2026-07-29	Unavailable	Unavailable	2 / 4
2026-07-30	Unavailable	Unavailable	2 / 4
2026-07-31	Unavailable	Unavailable	2 / 4
2026-08-01	Unavailable	Unavailable	2 / 4
2026-08-02	Unavailable	Unavailable	2 / 4
2026-08-03	Unavailable	Unavailable	3 / 4
2026-08-04	Unavailable	Unavailable	2 / 4
2026-08-05	Unavailable	Unavailable	2 / 4
2026-08-06	Unavailable	Unavailable	3 / 4
2026-08-07	Unavailable	Unavailable	2 / 4
2026-08-08	Unavailable	Unavailable	2 / 4
2026-08-09	Unavailable	Unavailable	3 / 4
2026-08-10	Unavailable	Unavailable	3 / 4
2026-08-12	Unavailable	Unavailable	3 / 4
2026-08-13	Unavailable	Unavailable	2 / 4
2026-08-14	Unavailable	Unavailable	2 / 4
2026-08-15	Unavailable	Unavailable	2 / 4
2026-08-16	Unavailable	Unavailable	2 / 4
2026-08-17	Unavailable	Unavailable	2 / 4
2026-08-18	Unavailable	Unavailable	2 / 4
2026-08-19	Unavailable	Unavailable	2 / 4
2026-08-20	Unavailable	Unavailable	3 / 4
2026-08-21	Unavailable	Unavailable	3 / 4
2026-08-22	Unavailable	Unavailable	3 / 4
2026-08-23	Unavailable	Unavailable	3 / 4
2026-08-24	Unavailable	Unavailable	3 / 4
2026-08-25	Unavailable	Unavailable	3 / 4
2026-08-26	Unavailable	Unavailable	3 / 4
2026-08-27	Unavailable	Unavailable	3 / 4
2026-08-28	Unavailable	Unavailable	3 / 4
2026-08-29	Unavailable	Unavailable	3 / 4
2026-08-30	Unavailable	Unavailable	3 / 4
2026-08-31	Unavailable	Unavailable	3 / 4
2026-09-01	Unavailable	Unavailable	3 / 4
2026-09-02	Unavailable	Unavailable	3 / 4
2026-09-03	Unavailable	Unavailable	3 / 4
2026-09-04	Unavailable	Unavailable	3 / 4
2026-09-05	Unavailable	Unavailable	3 / 4
2026-09-06	Unavailable	Unavailable	3 / 4
2026-09-07	Unavailable	Unavailable	3 / 4
2026-09-08	Unavailable	Unavailable	3 / 4
2026-09-09	Unavailable	Unavailable	3 / 4
2026-09-10	Unavailable	Unavailable	3 / 4
2026-09-11	Unavailable	Unavailable	3 / 4
2026-09-12	Unavailable	Unavailable	3 / 4
2026-09-13	Unavailable	Unavailable	3 / 4
2026-09-14	Unavailable	Unavailable	3 / 4
2026-09-15	Unavailable	Unavailable	3 / 4
2026-09-16	Unavailable	Unavailable	3 / 4
2026-09-17	Unavailable	Unavailable	3 / 4
2026-09-18	Unavailable	Unavailable	3 / 4
2026-09-19	Unavailable	Unavailable	3 / 4
2026-09-20	Unavailable	Unavailable	3 / 4
2026-09-21	Unavailable	Unavailable	3 / 4
2026-09-22	Unavailable	Unavailable	3 / 4
2026-09-23	Unavailable	Unavailable	3 / 4
2026-09-24	Unavailable	Unavailable	3 / 4
2026-09-25	Unavailable	Unavailable	3 / 4
2026-09-26	Unavailable	$39,990	4 / 5
2026-09-27	Unavailable	$39,990	4 / 5
2026-09-28	Unavailable	$39,990	4 / 5
2026-09-29	Unavailable	$39,990	4 / 5
2026-09-30	Unavailable	$39,990	4 / 5
2026-10-01	Unavailable	$39,990	4 / 5
2026-10-02	Unavailable	$39,990	4 / 5
2026-10-03	Unavailable	$39,990	4 / 5
2026-10-04	Unavailable	$39,990	4 / 5
2026-10-05	Unavailable	$39,990	4 / 5
2026-10-06	Unavailable	$39,990	4 / 5
2026-10-07	Unavailable	$39,990	4 / 5
2026-10-08	Unavailable	$39,990	4 / 5
2026-10-09	Unavailable	$39,990	4 / 5
2026-10-10	Unavailable	$39,990	4 / 5
2026-10-11	Unavailable	$39,990	4 / 5
2026-10-12	Unavailable	$39,990	4 / 5
2026-10-13	Unavailable	$39,990	4 / 5
2026-10-14	Unavailable	$39,990	4 / 5
2026-10-15	Unavailable	$39,990	4 / 5
2026-10-16	Unavailable	$39,990	4 / 5
2026-10-17	Unavailable	$39,990	4 / 5
2026-10-18	Unavailable	$39,990	4 / 5
2026-10-19	Unavailable	$39,990	4 / 5
2026-10-20	Unavailable	$39,990	4 / 5
2026-10-21	Unavailable	$39,990	4 / 5
2026-10-22	Unavailable	$39,990	4 / 5
2026-10-23	Unavailable	$39,990	4 / 5
2026-10-24	Unavailable	$39,990	4 / 5

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	3	0	0
2026-06-01	3	0	0
2026-07-01	3	0	0
2026-08-01	3	0	0
2026-09-01	4	0	0
2026-10-01	4	0	0

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 4 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Reduce cash operating expenses to $10.1M annuallyPublished status: Under Pressure
EPS loss narrows toward consensus estimatesPublished status: Broken
Successful authorization and utilization of Series A Preferred StockPublished status: Under Pressure

Next proof point

Nov 13, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

3.2%Typical daily move · historical

Downside history

-78.6%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Neonc Technologies Holdings Inc outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a speculative, loss-making biotech company, not an established earnings compounder. The long-term thesis is in a watch state: clinical milestones are progressing, but management volatility, weak recent performance, and high risk leave the business case fragile.

What's priced into Neonc Technologies Holdings Inc

The evidence gives no valuation measure or clear account of what market expectations assume, so whether NTHI is cheap or expensive versus peers cannot be assessed. Its priced-in fragility tier is low because no fragility gates fired, but that does not remove the underlying business risks.

What the fundamentals likely do

Over the multi-year view, NEO100 and NEO212 development is advancing, with management meeting stated clinical milestones and engaging the FDA on next steps. Expense control has mixed evidence, while recent financial performance is weak and the near-term risk of another earnings miss is elevated. A CEO transition and recent debt issuance add uncertainty around execution and capital allocation.

What Neonc Technologies Holdings Inc hinges on

The thesis depends on NEO100’s clinical results and regulatory path, and on progress toward a pivotal Phase 2 study for NEO212. Near term, a guidance cut or further weakening in jobs data could weigh on expectations and cyclical healthcare names; continued earnings strength and higher guidance from sector bellwethers could support sector momentum.